22157.jpg
Neuroendocrine Tumors (NETs) Market Research 2024-2030 with Analyst Recommendations - Establishment of Specialist Therapeutic Centers / Organize Campaigns to Raise Awareness
01 oct. 2024 06h48 HE | Research and Markets
Dublin, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The "Global Neuroendocrine Tumors (NETs) Market (2024 Edition): Analysis By Therapy (Somatostatin Analogs (SSAs), Targeted Therapy, Others), By Route of...
GMILogo_Vertical-Gradient.png
Multiple Myeloma Therapeutics Market to hit USD 44.2 billion by 2032, says Global Market Insights Inc.
30 sept. 2024 02h30 HE | Global Market Insights Inc.
Selbyville, Delaware, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Multiple Myeloma Therapeutics Market size was at approximately USD 25.4 billion in 2023 and will grow at 6.4% CAGR from 2024 to 2032,...
cropped-cropped-Logo-AlgoTx-couleur-1-228x81.png
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
24 sept. 2024 03h00 HE | AlgoTX
PARIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- AlgoTherapeutix (AlgoTx), a clinical stage biotechnology company developing a first-in-class therapeutic for peripheral neuropathic pain, ATX01, announced...
Global NTRK Fusion Gene Positive Advanced Solid Tumors Market
NTRK Fusion Gene Positive Advanced Solid Tumors Strategic Business Report 2024, with Coverage of Major Players such as Amoy Diagnostics, AnHeart Therapeutics, ARUP Laboratories, EntroGen and More
17 sept. 2024 08h00 HE | Research and Markets
Dublin, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The "NTRK Fusion Gene Positive Advanced Solid Tumors - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global...
factMR-logo.png
Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR
17 sept. 2024 06h00 HE | FACT.MR
Rockville, MD, Sept. 17, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a market research and competitive intelligence provider, the global chemotherapy induced nausea and vomiting treatment...
22157.jpg
Gastric Cancer Market Research Report 2024-2030 by Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Target Therapies, PD-1/PD-L1 Inhibitors, HER2 Antagonists VEGFR2 Antagonists
11 sept. 2024 11h03 HE | Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Gastric Cancer Market (2024 Edition): Analysis By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal...
Global Retinoblastoma Treatment Market
Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033
23 août 2024 11h47 HE | Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "Retinoblastoma Treatment Market Report, Global, 2024" report has been added to ResearchAndMarkets.com's offering. Market Growth TrajectoryGlobal...
Transparency Market Research
Bladder Cancer Therapeutics Market is Likely to Reach USD 456.3 million by 2034 at a CAGR of 4.8% | Report Analysis by Transparency Market Research Inc.
09 août 2024 10h18 HE | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research, Inc. , Aug. 09, 2024 (GLOBE NEWSWIRE) -- The global bladder cancer therapeutics market(방광암 치료제 시장) stood at US$ 271.4 million in...
Oncology/Cancer Drugs Market to Reach $335.2 Billion, Globally, by 2033 at 7.2% CAGR: Allied Market Research
01 août 2024 21h30 HE | Allied Analytics LLP
Wilmington, Delaware, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Oncology/Cancer Drugs Market by Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy...
22157.jpg
Chemotherapy Induced Peripheral Neuropathy Drug Pipeline Research 2024: Therapeutics Assessment by Product Type, Stage, Route of Administration, and Molecule Type
26 juin 2024 09h26 HE | Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.An insightful report...